Ovidrel FAERS Safety Signals: What the FDA Post-Market Data Means for You

What Is Ovidrel and Why Does the FDA Track It After Approval?

Ovidrel is a recombinant form of human chorionic gonadotropin (hCG) used as a "trigger shot" to complete the maturation of eggs and initiate ovulation in women undergoing controlled ovarian stimulation. The 250 mcg subcutaneous dose delivers a luteinizing hormone (LH) surge equivalent that the body would produce naturally at mid-cycle, but on a clinician-controlled timeline.

FDA approval is not the end of the safety story. It is the beginning of post-market surveillance. The FDA Adverse Event Reporting System (FAERS) is a pharmacovigilance database that collects voluntary and mandatory reports of adverse events and medication errors from consumers, healthcare providers, and manufacturers. Reports accumulate across years of real-world use, in populations far broader and more varied than those enrolled in pre-approval clinical trials.

For Ovidrel specifically, the pre-approval trials enrolled a narrow cohort: predominantly white women aged 18 to 39, most with unexplained infertility or polycystic ovary syndrome (PCOS), treated at academic fertility centers. Women with severe endometriosis, prior thromboembolic events, or significant cardiometabolic disease were largely excluded. That exclusion matters, because those are exactly the women who may now be receiving Ovidrel in community reproductive-endocrinology clinics.

Why Post-Market Surveillance Matters More in Fertility Medicine

Fertility drugs occupy an unusual regulatory position. They are given for a finite, defined purpose, in women who are otherwise healthy, yet they produce profound hormonal perturbations for days to weeks. A drug that looks safe in a 300-woman clinical trial may generate meaningful safety signals once millions of cycles have been logged.

The EMA's European Public Assessment Report (EPAR) for Ovidrel (choriogonadotropin alfa, brand name Ovitrelle in Europe) echoes the FDA's post-market findings, giving clinicians a transatlantic dataset to draw from.

Ovidrel FDA Approval: The Regulatory Baseline

The FDA approved Ovidrel on September 20, 2000 under NDA 021174. Approval was based on two key Phase III trials:

• A North American trial in 99 women with anovulatory or oligo-ovulatory infertility showed that Ovidrel 250 mcg produced an ovulation rate of 70 percent compared with 61 percent for urinary hCG 10,000 IU, with a statistically non-inferior safety profile.
• A European ART trial demonstrated equivalent rates of mature oocyte retrieval and clinical pregnancy compared with urinary hCG.

The recombinant formulation offered two practical advantages over urinary-derived hCG: no animal proteins (reducing injection-site reactions) and a precisely defined 250 mcg dose with batch-to-batch consistency. Those advantages translated into a rapid market uptake that now spans IUI (intrauterine insemination), IVF, and timed intercourse cycles globally.

What Changed at the Label Level Since 2000?

The current Ovidrel prescribing information retains the Pregnancy Category X designation and includes label updates that reflect post-market signals. These include:

• Strengthened language on OHSS, including the observation that severe OHSS may be life-threatening
• Addition of arterial thromboembolism (ATE) as a distinct risk separate from venous thromboembolism (VTE)
• Clarification that multiple gestation, including higher-order multiples, is a direct consequence of multi-follicle stimulation protocols, not an intrinsic property of hCG itself

The label's indication language is precise: Ovidrel is approved for final follicular maturation and early luteinization in women undergoing superovulation AND for induction of ovulation and pregnancy in anovulatory/oligo-ovulatory women in whom the cause of infertility is functional and not primary ovarian failure.

The FAERS Picture: Top Safety Signals by Report Volume

FAERS data for choriogonadotropin alfa (searching both "Ovidrel" and "choriogonadotropin alfa" as product names) consistently surface the following signals. These are reports, not confirmed causal relationships, but disproportionality analysis using reporting odds ratios (RORs) flags signals that exceed background noise.

1. Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is the most-reported serious adverse event for Ovidrel in FAERS and the one given the most detailed label treatment. Severe OHSS carries an incidence of approximately 0.1 to 2 percent of ART cycles, though mild-to-moderate OHSS may affect up to 33 percent of cycles.

The physiology is specific to the female body: hCG binds LH/hCG receptors on granulosa and theca cells, driving VEGF (vascular endothelial growth factor) release, which increases capillary permeability. Fluid shifts into the third space (peritoneum, pleura, pericardium), causing ascites, hemoconcentration, and, in severe cases, renal failure or acute respiratory distress syndrome.

Who is at highest risk?

• Women with PCOS: the most consistently identified risk factor. PCOS ovaries carry a higher antral follicle count and more LH/hCG receptors per unit of ovarian tissue, amplifying the VEGF cascade.
• Anti-Mullerian Hormone (AMH) above 3.4 ng/mL: a pre-cycle marker used by many reproductive endocrinologists to stratify risk.
• Prior OHSS episode: repeat risk is substantial.
• Age below 35 and low BMI.

OHSS risk-mitigation strategies the label and ASRM support:

Freeze-all embryo strategies (deferring embryo transfer) eliminate the second hCG surge from an early pregnancy. ASRM practice guidelines note that segmentation of the IVF cycle (trigger, retrieve, freeze, defer transfer) is the most effective single intervention for high-risk patients.

Dopamine agonists such as cabergoline 0.5 mg daily for 8 days post-trigger may reduce moderate OHSS rates by approximately 65 percent in high-risk patients, though the data come primarily from studies in PCOS women in Europe and have not been replicated in large US RCTs.

2. Thromboembolic Events

The Ovidrel label carries a specific warning about arterial thromboembolism, and FAERS reports include both venous (deep vein thrombosis, pulmonary embolism) and arterial (stroke, myocardial infarction) events. These events are rare in absolute terms but carry high severity scores in pharmacovigilance disproportionality analyses.

The mechanism is multifactorial: estradiol elevations from stimulated follicles activate hepatic clotting factor synthesis, OHSS-associated hemoconcentration raises blood viscosity, and immobility during bed rest for OHSS or early pregnancy compounds the picture.

Women with thrombophilia (Factor V Leiden, antiphospholipid syndrome, Protein C or S deficiency) face a compounding risk. A 2016 analysis in Fertility and Sterility documented ATE rates of approximately 3 per 10,000 ART cycles, concentrated in women with pre-existing thrombotic risk factors.

The practical implication: if you have a personal or family history of clotting disorders, your reproductive endocrinologist should screen you with a thrombophilia panel before initiating stimulation. Anticoagulation bridging is sometimes used, though no RCT specifically in Ovidrel-triggered cycles exists. This is an area where women's trial data remain thin. Be direct with your provider about family history.

3. Multiple Gestation

Multiple gestation is not a pharmacologic adverse effect of hCG itself but of the multi-follicle environment in which the trigger is used. Yet it appears prominently in FAERS narratives because the consequences, preterm birth, low birthweight, maternal hemorrhage, and NICU admission, are serious and sometimes fatal.

ASRM's 2021 guidelines on multiple gestation in ART recommend single embryo transfer (SET) for most patients, which has substantially reduced IVF-related twin rates. But in IUI cycles where Ovidrel is used after gonadotropin stimulation, controlling the number of preovulatory follicles remains the primary safeguard. Most protocols cancel or convert IUI cycles to IVF if three or more mature follicles are present.

4. Injection-Site Reactions and Allergic Responses

FAERS includes a cluster of injection-site pain, erythema, and bruising reports, as well as systemic hypersensitivity reactions including urticaria and, in rare cases, anaphylaxis. The recombinant formulation removed urinary proteins, but E. Coli-derived production introduces its own protein impurities. Women with known hypersensitivity to E. Coli-derived preparations should discuss alternatives with their physician.

5. Ectopic Pregnancy

Ectopic pregnancy appears in FAERS reports for all gonadotropin and hCG products. Ovidrel does not cause ectopic pregnancy, but because it is used in populations with underlying tubal pathology (prior PID, endometriosis, prior tubal surgery), the background ectopic rate in ART populations is higher than in spontaneous conception. The CDC estimates a background ectopic rate of 1 to 2 percent of all pregnancies, while IVF populations see rates closer to 2 to 5 percent.

The first beta-hCG draw after Ovidrel trigger requires careful timing. Because exogenous hCG from the trigger can remain detectable for 10 to 14 days, a positive urine pregnancy test in that window may reflect the drug, not an implanted embryo. Serum beta-hCG with serial doubling is the correct surveillance tool.

Sex-Specific Pharmacokinetics: How Ovidrel Behaves in the Female Body

Understanding how choriogonadotropin alfa moves through a woman's body helps explain both its therapeutic effect and its risk profile. Here is a concise pharmacokinetic framework specifically for female patients, because nearly all PK data for hCG products come from female subjects in fertility trials.

Absorption: After a 250 mcg subcutaneous injection, peak serum hCG concentrations (Cmax) of approximately 121 IU/L are reached at a median Tmax of 24 hours. This is slower than intramuscular injection but produces equivalent LH-surge mimicry.

Distribution: hCG has a volume of distribution of approximately 5.9 L, suggesting limited tissue penetration beyond the vascular and reproductive compartments. The ovarian LH/hCG receptor is the primary target.

Elimination: The mean terminal half-life is approximately 29 hours for Ovidrel, shorter than urinary hCG (36 hours), which is pharmacologically relevant for FAERS signal interpretation. Shorter half-life may reduce the duration of OHSS-driving receptor stimulation, though head-to-head OHSS-rate data do not show a clinically meaningful difference.

Hormonal status interaction: In women with PCOS who have chronically elevated baseline LH, the endogenous LH milieu may alter receptor sensitivity. Downregulation protocols (GnRH agonist or antagonist) standardize this before trigger administration, but in unprotocolled cycles or IUI without a GnRH antagonist, the receptor context differs meaningfully.

Menstrual cycle phase: Ovidrel is always given in the late follicular phase, when estradiol is peaking and LH receptors on granulosa cells are maximally expressed. This is not variable across cycles once stimulation is optimized, but it means that any deviation in the stimulation protocol, such as a premature LH surge before trigger, can substantially change the downstream risk profile.

Life-Stage Guide: Who Receives Ovidrel and What Changes

Reproductive Years: Trying to Conceive (TTC) With or Without ART

This is the core indicated population. Women in their 20s and early 30s who are ovulatory but undergoing IVF receive Ovidrel primarily for timing precision. Women who are anovulatory (including PCOS) receive it after stimulation with clomiphene citrate, letrozole, or FSH to complete ovulation.

PCOS deserves a specific note. Up to 70 percent of women with PCOS are anovulatory, making them the single largest subgroup receiving ovulation induction triggers. They are also the subgroup at highest OHSS risk, which creates a therapeutic tension that requires individualized dosing strategy, sometimes including the use of a GnRH agonist trigger (leuprolide) instead of Ovidrel in antagonist-protocol IVF cycles, to reduce OHSS risk while still achieving final maturation.

Perimenopause: When Fertility Treatment Overlaps With Hormonal Transition

Women in their early-to-mid 40s may pursue fertility treatment, including egg freezing or IVF with their own eggs, during the perimenopause transition. FSH levels in perimenopausal women are intermittently elevated, which complicates stimulation response prediction. Ovidrel use in this group is the same label indication, but the expected oocyte yield is lower and the risk of poor response (rather than OHSS) predominates.

No dedicated FAERS signal analysis for perimenopausal women receiving Ovidrel exists in the published literature. This is a meaningful evidence gap.

Postpartum and Lactation

Fertility treatment rarely occurs in the immediate postpartum period, but women who have recently delivered and are lactating may pursue a subsequent IVF cycle. Ovidrel is given as a single injection; its 29-hour half-life means it would be largely cleared within 5 to 7 days. No human milk transfer data for recombinant hCG are published. Because ovarian stimulation is typically paused entirely during lactation, co-administration with active breastfeeding is uncommon in clinical practice.

Pregnancy and Lactation Safety: The Required Full Picture

Pregnancy Category X: What This Actually Means for Ovidrel

The Ovidrel prescribing information carries a Pregnancy Category X designation under the legacy FDA classification system. This does not mean the drug causes harm if a pregnancy is already present; it means the drug is contraindicated for use in a woman who is already pregnant.

The distinction matters in clinical practice. Ovidrel IS the drug that initiates the hormonal environment that allows implantation and early pregnancy. It is given BEFORE a confirmed pregnancy. If a woman becomes pregnant in a cycle where Ovidrel was used as a trigger, that is the intended outcome of therapy. The Category X warning applies to scenarios such as giving hCG to a woman with an already-confirmed pregnancy, or using it outside of a monitored fertility protocol.

Animal data: Studies in pregnant rats and rabbits given hCG at multiples of the human dose showed dose-dependent teratogenicity. These findings are not considered directly extrapolable to the single-trigger human dose but inform the label's conservative stance.

Human data: No controlled studies of Ovidrel exposure in established human pregnancy exist. Case reports of inadvertent Ovidrel administration in early confirmed pregnancy have not documented a consistent teratogenic pattern, but the dataset is far too small to draw conclusions.

Contraception Requirement

Ovidrel is used to support pregnancy. There is no contraception requirement associated with its use. However, women receiving Ovidrel in a monitored fertility protocol who do not achieve pregnancy in a given cycle should discuss next-cycle timing with their reproductive endocrinologist. Women not yet ready to attempt pregnancy should not use Ovidrel outside a monitored protocol.

Lactation

No data exist on hCG transfer into human breast milk for the recombinant formulation. Endogenous hCG is present in the serum of pregnant women and may transfer into colostrum at low levels, but the clinical significance for a nursing infant is unknown. Because fertility treatment cycles and active lactation rarely overlap, this is primarily a theoretical concern rather than a common clinical scenario.

What the Ovidrel Label Says: A Plain-Language Summary

The current Ovidrel prescribing information runs to 22 pages. Here is what matters most for a woman reading it:

Contraindications:

• Primary ovarian failure
• Uncontrolled thyroid or adrenal dysfunction
• Intracranial lesion (e.g., pituitary tumor)
• Abnormal uterine bleeding of undetermined cause
• Ovarian cyst or ovarian enlargement not due to PCOS
• Pregnancy (see above)
• Known hypersensitivity to hCG or any component

Warnings and Precautions:

• OHSS: "Ovarian Hyperstimulation Syndrome (OHSS) is a medical event distinct from uncomplicated ovarian enlargement... Severe OHSS may be life-threatening."
• Arterial thromboembolism: "Thromboembolic events, both in association with and separate from OHSS, have been reported following therapy with gonadotropins and hCG."
• Multiple births: "Advise patients of the potential for multiple births before starting treatment."

Dosage: 250 mcg subcutaneous injection, given 1 day following the last dose of a follicle-stimulating agent, administered 34 to 36 hours before oocyte retrieval (in ART) or at the time predicted to induce optimal ovulation.

Who Is Right for Ovidrel, and Who Should Be Extra Cautious

Good Candidates

• Women undergoing IVF or IUI with gonadotropin stimulation who have a normal-to-low antral follicle count and AMH below 3.0 ng/mL
• Women with anovulation due to hypothalamic causes (not primary ovarian failure)
• Women who have not responded to oral ovulation induction alone
• Women with unexplained infertility using timed intercourse or IUI

Candidates Who Need Additional Risk Stratification

• Women with PCOS and AMH above 3.4 ng/mL (high OHSS risk; consider GnRH agonist trigger instead if on an antagonist protocol)
• Women with a prior OHSS episode
• Women with personal or family history of thrombophilia or thromboembolic events
• Women with hypothyroidism or hyperthyroidism that is not yet optimized (thyroid status affects stimulation response and early pregnancy outcomes)
• Women with endometriosis affecting tubal anatomy (ectopic pregnancy risk)
• Women with a body weight below 50 kg or above 100 kg (PK data are sparse at the extremes; the 250 mcg fixed dose may not be equally distributed)

Who Should Not Use Ovidrel

Women with primary ovarian failure, active pituitary or hypothalamic disease, ovarian cysts of unknown origin, or confirmed pregnancy should not receive Ovidrel. This is not negotiable; it is the label's black-and-white contraindication list.

What the Evidence Gap Looks Like for Women

Women have been historically under-represented in pharmacovigilance methodology papers, even when the drug in question is used exclusively in women. Three evidence gaps are worth naming directly for Ovidrel:

Gap 1: FAERS reporting quality. FAERS relies on voluntary reporting. Fertility clinics report adverse events at variable rates. OHSS cases managed entirely in-clinic without hospitalization may not be reported. The true incidence of mild-to-moderate OHSS is likely higher than FAERS suggests.

Gap 2: Race and ethnicity. The pre-approval Ovidrel trials enrolled primarily white European and North American women. PCOS prevalence and phenotype differ by ethnicity. Black and Hispanic women with PCOS may have different baseline LH receptor expression and different OHSS risk profiles, but no published subgroup analysis for Ovidrel specifically addresses these differences.

Gap 3: Long-term outcomes. FAERS captures events within a relatively short reporting window. Long-term ovarian reserve effects, cancer risk (particularly ovarian and breast cancer in BRCA carriers who undergo multiple stimulation cycles), and cardiovascular sequelae of repeated estradiol surges are not captured systematically. A 2019 NEJM study on fertility treatments and cancer risk found no significant increase in ovarian cancer with gonadotropin use at population level, but BRCA1/2 carriers were not analyzed separately.

Talking to Your Fertility Team About FAERS Signals

Your reproductive endocrinologist reviews FAERS signals as part of continuing medical education, but you can bring specific questions to your appointment. Here is a practical framework:

Ask your provider: "What is my personal OHSS risk score based on my AFC and AMH?" A single AMH value and antral follicle count on a baseline ultrasound are the two most accessible risk-stratification tools.

Ask: "If I am high-risk for OHSS, would a GnRH agonist trigger be appropriate instead of Ovidrel?" In antagonist-protocol IVF, a GnRH agonist trigger (leuprolide 1 to 2 mg) can replace Ovidrel and dramatically reduce OHSS risk, at the cost of slightly lower luteal-phase support requirements and, in some studies, marginally lower fresh-transfer pregnancy rates.

Ask: "Should I have a thrombophilia panel before my first stimulation cycle?" If you have a first-degree relative with a deep vein thrombosis or pulmonary embolism before age 50, the answer from most reproductive endocrinologists is yes.

Ovidrel is one of the most precisely characterized fertility drugs on the US market, with 25 years of post-market data, a well-described FAERS signal profile, and a label that is regularly reviewed. Your job as the patient is to arrive at the conversation knowing your own risk factors.